Emerging in the arena of obesity management, retatrutide represents a distinct strategy. Beyond many current medications, retatrutide operates as a double agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) receptors. The concurrent engagement encourages various advantageous